-+ 0.00%
-+ 0.00%
-+ 0.00%

Jiangsu Recbio says NMPA accepts filing for REC610 shingles vaccine approval

PUBT·07/23/2026 10:25:56
Listen to the news
Jiangsu Recbio says NMPA accepts filing for REC610 shingles vaccine approval
  • Jiangsu Recbio’s NMPA drug review center accepted the REC610 shingles vaccine marketing application on Dec. 29, 2025 (CXSS2500145).
  • Clinical trial site inspection, manufacturing registration inspection completed; review process continues.
  • 9-valent HPV vaccine filing missed the June 30, 2026 submission target; timeline reset while materials are finalized.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Recbio Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254396), on July 23, 2026, and is solely responsible for the information contained therein.